BIM
PGNX

Bogle Investment Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Bogle Investment Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-115,008
Closed -$993K – 416
2016
Q4 		$993K Buy
+115,008
New +$850K 0.07% 254
2015
Q4 		– Sell
-790,381
Closed -$4.52M – 469
2015
Q3 		$4.52M Buy
+790,381
New +$6.06M 0.32% 113
2013
Q4 		– Sell
-338,411
Closed -$1.7M – 378
2013
Q3 		$1.7M Buy
+338,411
New +$1.84M 0.17% 182

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Bogle Investment Management's PGNX Position: Q1 2017 in Review

Bogle Investment Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2017, closing a stake of 115,008 shares — an estimated $993K sold.

Bogle Investment Management first reported a position in PGNX in Q3 2013 and held it in 3 quarters. The position peaked at $4.52M in Q3 2015. 159 funds tracked by Wall St. Rank hold PGNX as of Q1 2017.

  • Bogle Investment Management reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Bogle Investment Management sold 115,008 Progenics Pharmaceuticals Inc shares in Q1 2017, an estimated $993K.
  • Bogle Investment Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and held it in 3 quarters.
  • Bogle Investment Management's Progenics Pharmaceuticals Inc position peaked at $4.52M in Q3 2015.
  • 159 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2017.

Based on Bogle Investment Management's 13F filing for Q1 2017, filed 12 May 2017.